Sistemic announce new miRNA publication exploring the functional differences between MSCs derived from different tissues and the continued expansion of patent portfolio in the exosome and predictive biomarker space.

Glasgow, Scotland. Sistemic Ltd. announced today that it has recently published, in collaboration with colleagues at Institute of Infection, Inflammation and Immunity, Glasgow Biomedical Research Centre, University of Glasgow, evidence of significant and potentially functionally relevant differences between MSCs from Olfactory Mucosa and from Bone Marrow revealed by miRNA profiling.

Sistemic Ltd Announce Expansion of Patent Portfolio Covering the Use of microRNAs as Predictive Analytes for Cellular Function

Glasgow, United Kingdom; 16^th July 2020: Sistemic Ltd. is pleased to announce that it has received Notification of Intention to Grant by the United Kingdom Intellectual Property Office (UKIPO) for the patent application entitled “Functional Prediction of MSCs” (UK Patent Application No. 1608086.3).

Read more about Sistemic Ltd Announce Expansion of Patent Portfolio Covering the Use of microRNAs as Predictive Analytes for Cellular Function

Sistemic is Back Open for Business

On the 24th March 2020 we let everyone know that in order to comply with the UK and Scottish Governments' lock down restrictions, the company would temporarily close at the end of the working day 24th March 2020.

We have now put the necessary IT infrastructure to allow all staff to work from home, and also the social distancing measures to allow lab work to be safely carried out in compliance with the UK and Scottish Governments' social distancing measures.

Read more about Sistemic is Back Open for Business

Sistemic announce a new article published on RegMedNet titled “In vitro assays for residual pluripotent stem cells in derived cell therapy products: what’s the current state of play?”

Sistemic are delighted to announce a new article published on RegMedNet titled “In vitro assays for residual pluripotent stem cells in derived cell therapy products: what’s the current state of play?”.

Read more about Sistemic announce a new article published on RegMedNet titled “In vitro assays for residual pluripotent stem cells in derived cell therapy products: what’s the current state of play?”

COVID-19 and Sistemic shutdown

To all our clients, suppliers and partners,

We are taking this opportunity to let you know that as of 20.30 GMT 23rd March 2020 the UK and Scottish Governments issued further legally enforced social distancing measures, and as part of this, have instructed all non-essential businesses to close with immediate effect. They have stated that this situation will be reviewed following an initial 3 week period, in the first instance.

Read more about COVID-19 and Sistemic shutdown

Sistemic, COVID-19 and business continuity

Hello,

We would like to provide you with an update regarding our plans for dealing with the COVID-19 outbreak, as well as our commitment to working with you on your important projects. We are following UK Public Health Policy and all Government advice to ensure that we fully comply with guidance as it occurs.

Read more about Sistemic, COVID-19 and business continuity

Recent Tweets

EPO granted Sistemic the Patent covering the use of microRNAs for quality assessment of stem cell therapy products https://t.co/diZeCjyi54 — Tweeted: Thu, 03/28/2019 - 15:55

Current Location

News

Pages

Recent News

Applications & Case Studies

Recent Tweets